Amgen (AMGN) Other Operating Expenses (2009 - 2026)
Amgen (AMGN) posted quarterly Other Operating Expenses of $2.6 billion for Q1 2026, down 11.35% year-over-year from $3.0 billion in Q1 2025, and down 11.59% quarter-over-quarter from $3.0 billion in Q4 2025.
Amgen (AMGN) Other Operating Expenses (2009 - 2026) Analysis & Trends
Amgen's Other Operating Expenses history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 11.35% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $11.7 billion (down 7.33% YoY), while the FY2025 annual figure was $12.0 billion, down 6.39% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $2.6 billion, down from $3.0 billion in the prior quarter.
- The five-year high for Other Operating Expenses was $3.3 billion in Q3 2024, with the low at $1.6 billion in Q1 2022.
- The 5-year median for Other Operating Expenses is $3.0 billion (2025), against an average of $2.6 billion.
- The sharpest annual moves came in 2022 and 2023: Other Operating Expenses slumped 34.69% in 2022, then jumped 81.96% in 2023.
- Amgen's Other Operating Expenses stood at $1.7 billion in 2022, then surged by 81.96% to $3.1 billion in 2023, then retreated by 0.16% to $3.1 billion in 2024, then slipped by 4.37% to $3.0 billion in 2025, then retreated by 11.59% to $2.6 billion in 2026.
- Business Quant data shows AMGN's Other Operating Expenses at $2.6 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.93 Bn |
| Mar 31, 2026 | 2.63 Bn |
| Dec 31, 2025 | 2.98 Bn |
| Sep 30, 2025 | 3.08 Bn |
| Jun 30, 2025 | 3.01 Bn |
| Mar 31, 2025 | 2.97 Bn |
| Dec 31, 2024 | 3.11 Bn |
| Sep 30, 2024 | 3.31 Bn |
| Jun 30, 2024 | 3.24 Bn |
| Mar 31, 2024 | 3.20 Bn |
| Dec 31, 2023 | 3.12 Bn |
| Sep 30, 2023 | 2.45 Bn |
| Jun 30, 2023 | 1.90 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 1.59 Bn |
| Jun 30, 2022 | 2.05 Bn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.72 Bn |
| Sep 30, 2021 | 1.61 Bn |